IL-15 treatment with or without vaccine for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has returned after initial treatment, shown by a rising PSA level.
- You had a type of targeted radiation therapy (SBRT) for spots found on a PSMA scan, and your PSA went up at least 25% after that radiation.
- You are at least 18 years old and in good overall health (able to do daily activities).
- Your kidney and liver function tests are within acceptable limits.
- You do not have active infections like HIV or hepatitis, or a serious autoimmune disease.
- You have not had other cancer treatments (including steroids or hormone pills) in the last month, except as allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine that may help your immune system fight prostate cancer cells. If you have low- or intermediate-risk prostate cancer and are under active surveillance, this vaccine might slow or prevent the cancer from growing.
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
This trial combines two immune-boosting treatments, Sipuleucel-T and N-803, to see if they can better fight prostate cancer that has spread and stopped responding to hormone therapy. It aims to help your immune system attack the cancer more effectively.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.